130 related articles for article (PubMed ID: 11920615)
1. Immunotherapy with recombinant SFV-replicons expressing the P815A tumor antigen or IL-12 induces tumor regression.
Colmenero P; Chen M; Castaños-Velez E; Liljeström P; Jondal M
Int J Cancer; 2002 Apr; 98(4):554-60. PubMed ID: 11920615
[TBL] [Abstract][Full Text] [Related]
2. Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene.
Colmenero P; Liljeström P; Jondal M
Gene Ther; 1999 Oct; 6(10):1728-33. PubMed ID: 10516722
[TBL] [Abstract][Full Text] [Related]
3. [Preventive and therapeutic effect of genetic vaccine based on recombinant alpha virus against mouse mastocytoma P815].
Ni B; Yang RG; Li YQ; Wu YZ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Jan; 20(1):45-8. PubMed ID: 15182620
[TBL] [Abstract][Full Text] [Related]
4. Induction of P815 tumor immunity by DNA-based recombinant Semliki Forest virus or replicon DNA expressing the P1A gene.
Ni B; Lin Z; Zhou L; Wang L; Jia Z; Zhou W; Diciommo DP; Zhao J; Bremner R; Wu Y
Cancer Detect Prev; 2004; 28(6):418-25. PubMed ID: 15582265
[TBL] [Abstract][Full Text] [Related]
5. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer.
Riezebos-Brilman A; Walczak M; Regts J; Rots MG; Kamps G; Dontje B; Haisma HY; Wilschut J; Daemen T
Gene Ther; 2007 Dec; 14(24):1695-704. PubMed ID: 17928874
[TBL] [Abstract][Full Text] [Related]
6. Recombinant Semliki Forest virus vaccine vectors: the route of injection determines the localization of vector RNA and subsequent T cell response.
Colmenero P; Berglund P; Kambayashi T; Biberfeld P; Liljeström P; Jondal M
Gene Ther; 2001 Sep; 8(17):1307-14. PubMed ID: 11571567
[TBL] [Abstract][Full Text] [Related]
7. Treatment of rapidly growing K-BALB and CT26 mouse tumours using Semliki Forest virus and its derived vector.
Smyth JW; Fleeton MN; Sheahan BJ; Atkins GJ
Gene Ther; 2005 Jan; 12(2):147-59. PubMed ID: 15372069
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in mice.
Lyons JA; Sheahan BJ; Galbraith SE; Mehra R; Atkins GJ; Fleeton MN
Gene Ther; 2007 Mar; 14(6):503-13. PubMed ID: 17167497
[TBL] [Abstract][Full Text] [Related]
9. Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography.
Asselin-Paturel C; Lassau N; Guinebretière JM; Zhang J; Gay F; Bex F; Hallez S; Leclere J; Peronneau P; Mami-Chouaib F; Chouaib S
Gene Ther; 1999 Apr; 6(4):606-15. PubMed ID: 10476220
[TBL] [Abstract][Full Text] [Related]
10. Induction of apoptosis in BCL-2-expressing rat prostate cancer cells using the Semliki Forest virus vector.
Murphy AM; Sheahan BJ; Atkins GJ
Int J Cancer; 2001 Nov; 94(4):572-8. PubMed ID: 11745446
[TBL] [Abstract][Full Text] [Related]
11. Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor.
Näslund TI; Uyttenhove C; Nordström EK; Colau D; Warnier G; Jondal M; Van den Eynde BJ; Liljeström P
J Immunol; 2007 Jun; 178(11):6761-9. PubMed ID: 17513723
[TBL] [Abstract][Full Text] [Related]
12. Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12.
Chikkanna-Gowda CP; Sheahan BJ; Fleeton MN; Atkins GJ
Gene Ther; 2005 Aug; 12(16):1253-63. PubMed ID: 15944731
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant administration of Semliki Forest virus expressing interleukin-12 combined with attenuated Salmonella eradicates breast cancer metastasis and achieves long-term survival in immunocompetent mice.
Kramer MG; Masner M; Casales E; Moreno M; Smerdou C; Chabalgoity JA
BMC Cancer; 2015 Sep; 15():620. PubMed ID: 26347489
[TBL] [Abstract][Full Text] [Related]
14. Induction of specific human primary immune responses to a Semliki Forest virus-based tumor vaccine in a Trimera mouse model.
Ni B; Gao W; Zhu B; Lin Z; Jia Z; Zhou W; Zhao J; Wang L; Wu Y
Cancer Immunol Immunother; 2005 May; 54(5):489-98. PubMed ID: 15750833
[TBL] [Abstract][Full Text] [Related]
15. Induction of a therapeutic antitumor immunological response by intratumoral injection of genetically engineered Semliki Forest virus to produce interleukin-12.
Yamanaka R; Zullo SA; Tanaka R; Ramsey J; Blaese M; Xanthopoulos KG
Neurosurg Focus; 2000 Dec; 9(6):e7. PubMed ID: 16817690
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12.
Quetglas JI; Dubrot J; Bezunartea J; Sanmamed MF; Hervas-Stubbs S; Smerdou C; Melero I
Mol Ther; 2012 Sep; 20(9):1664-75. PubMed ID: 22735380
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of human lung carcinoma cell growth by apoptosis induction using Semliki Forest virus recombinant particles.
Murphy AM; Morris-Downes MM; Sheahan BJ; Atkins GJ
Gene Ther; 2000 Sep; 7(17):1477-82. PubMed ID: 11001367
[TBL] [Abstract][Full Text] [Related]
18. Short-term intratumoral interleukin-12 expressed from an alphaviral vector is sufficient to induce an efficient antitumoral response against spontaneous hepatocellular carcinomas.
Rodriguez-Madoz JR; Zabala M; Alfaro M; Prieto J; Kramer MG; Smerdou C
Hum Gene Ther; 2014 Feb; 25(2):132-43. PubMed ID: 24219025
[TBL] [Abstract][Full Text] [Related]
19. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]